Tianjin expert consensus on the management of intestinal fecal microbiota transplantation (2025 edition)

doi:10.11958/20252240

Abstract

Abstract:

Fecal microbiota transplantation (FMT) is a novel medical technology targeting gut microbiota for disease intervention. It offers innovative treatment strategies for various intestinal and extraintestinal refractory disorders, overcoming the therapeutic limitation of traditional therapies in certain diseases. Currently, FMT has established mature application systems in multiple regions of China, but its clinical practice within Tianjin area still needs to be standardized and managed. With the rapid advancement of FMT research, innovative strategies such as washed microbiota transplantation (WMT), donor-recipient precision matching and intelligent predictive assessment of efficacy have emerged, driving its in-depth development towards standardization and precision. Against this backdrop, in order to promote the application and development of FMT in this region, Tianjin Digestive Quality Control Committee organized experts to develop the “Tianjin Expert Consensus on the Management of Fecal Microbiota Transplantation” based on the 2022 and 2023 expert consensus standards and integrate the characteristics of regional medical practices. The consensus systematically addresses the management requirements for all aspects of FMT technology. It proposes 15 targeted recommendations from two dimensions: standardization of technical operations and innovative expansion of clinical applications. The goal is to provide scientific and standardized practical guidelines for promoting FMT diagnosis and treatment in Tianjin.

Key words: fecal microbiota transplantation, clinical practice, standardization, management, consensus

CLC Number:

R456.9，R197

Figures/Tables 3

References 49

[1]	ALLEGRETTI J R, MULLISH B H, KELLY C, et al. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications[J]. Lancet, 2019, 394(10196):420-431. doi:10.1016/S0140-6736(19)31266-8.
[2]	郭智, 王强. 肠菌移植制备和质控实验室标准化技术规范中国专家共识(2023版)[J]. 中国微生态学杂志, 2024, 36(6):705-711,717.
	GUO Z, WANG Q. Chinese expert consensus on standardized technical specifications for laboratory preparation and quality control of fecal microbiota transplantation(2023 edition)[J]. Chin J Microecol, 2024, 36(6):705-711,717. doi:10.13381/j.cnki.cjm.202406013.
[3]	ZHANG F, CUI B, HE X, et al. Microbiota transplantation:concept,methodology and strategy for its modernization[J]. Protein Cell, 2018, 9(5):462-473. doi:10.1007/s13238-018-0541-8.
[4]	ABY E S, VAUGHN B P, ENNS E A, et al. Cost-effectiveness of Fecal microbiota transplantation for first recurrent clostridioides difficile infection[J]. Clin Infect Dis, 2022, 75(9):1602-1609. doi:10.1093/cid/ciac207.
[5]	BIAZZO M, DEIDDA G. Fecal microbiota transplantation as new therapeutic avenue for human diseases[J]. J Clin Med, 2022, 11(14):4119. doi:10.3390/jcm11144119.
[6]	YI D, LI T, XIAO Y, et al. Fecal microbiota transplantation for the treatment of intestinal and extra-intestinal diseases:Mechanism basis,clinical application,and potential prospect[J]. Bioeng Transl Med, 2025, 10(2):e10728. doi:10.1002/btm2.10728.
[7]	CHEN Q, WU C, XU J, et al. Donor-recipient intermicrobial interactions impact transfer of subspecies and fecal microbiota transplantation outcome[J]. Cell Host Microbe, 2024, 32(3):349-365.e4. doi:10.1016/j.chom.2024.01.013.
[8]	YU Y, WANG W, ZHANG F. The next generation fecal microbiota transplantation:to transplant bacteria or virome[J]. Adv Sci(Weinh), 2023, 10(35):e2301097. doi:10.1002/advs.202301097.
[9]	LIU Y, LI X, CHEN Y, et al. Fecal microbiota transplantation:application scenarios,efficacy prediction,and factors impacting donor-recipient interplay[J]. Front Microbiol, 2025, 16:1556827. doi:10.3389/fmicb.2025.1556827.
[10]	国家卫生健康委员会医院管理研究所, 中华医学会肠外肠内营养学分会, 中华医学会肠外肠内营养学分会肠道微生态协作组. 肠道菌群移植临床应用管理中国专家共识(2022版)[J]. 中华胃肠外科杂志, 2022, 25(9):747-756.
	National Institute of Hospital Administration,NHC,Society of Parenteral and Enteral Nutrition, Chinese Medical Association,Intestinal Microecology Cooperative Group, Chinese Society for Parenteral and Enteral Nutrition. Expert consensus on clinical application management of fecal microbiota transplantation(2022 edition)[J]. Chin J Gastrointest Surg, 2022, 25(9):747-756. doi:10.3760/cma.j.cn441530-20220725-00324.
[11]	天津市抗癌协会癌症康复与姑息治疗专业委员会, 天津市医师协会肿瘤多学科诊疗专业委员会. 难治性化疗相关性恶心呕吐防治的天津专家共识(2025版)[J]. 天津医药, 2025, 53(1):1-8.
	Tianjin Anti-Cancer Association Committee of Rehabilitation and Palliative Care, Tianjin Medical Doctor Association Committee of Tumor Multidisciplinary Diagnosis and Treatment. Tianjin expert consensus on the prevention and treatment of refractory chemotherapy-related nausea and vomiting(2025 edition)[J]. Tianjin Med J, 2025, 53(1):1-8. doi:10.11958/20240783.
[12]	PORCARI S, BENECH N, VALLES-COLOMER M, et al. Key determinants of success in fecal microbiota transplantation:From microbiome to clinic[J]. Cell Host Microbe, 2023, 31(5):712-733. doi:10.1016/j.chom.2023.03.020.
[13]	中华医学会肠外肠内营养学分会, 中国人体健康科技促进会肠道微生态与肠菌移植专业委员会, 上海市预防医学会肠道微生态专业委员会. 肠菌移植治疗炎症性肠病专家共识(2025版)[J]. 中华胃肠外科杂志, 2025, 28(3):225-235.
	Parenteral and Enteral Nutrition Branch of the Chinese Medical Association,Chinese Society for the Promotion of Human Health Science and Technology, Committee on Gut Microecology and Fecal Microbiota Transplantation, Shanghai Preventive Medicine Association. Consensus of Chinese experts on gut microbiota and fecal microbiota transplantation in inflammatory bowel disease(2025 edition)[J]. Chin J Gastrointest Surg, 2025, 28(3):225-235. doi:10.3760/cma.j.cn441530-20241224-00422.
[14]	WANG Y, ZHANG S, BORODY T J, et al. Encyclopedia of fecal microbiota transplantation:a review of effectiveness in the treatment of 85 diseases[J]. Chin Med J(Engl), 2022, 135(16):1927-1939. doi:10.1097/CM9.0000000000002339.
[15]	CAO H, LIU X, AN Y, et al. Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine[J]. Sci Rep, 2017, 7(1):10322. doi:10.1038/s41598-017-10835-8.
[16]	许梦雀, 曹海龙, 曹晓沧, 等. 粪菌移植治疗溃疡性结肠炎汇总分析[J]. 中国实用内科杂志, 2015, 35(9):790-791.
	XU M Q, CAO H L, CAO X C, et al. A pooling analysis of fecal microbiota transplantation in treatment of ulcerative colitis[J]. Chinese Journal of Practical Internal Medicine, 2015, 35(9):790-791. doi:10.7504/nk201508050.
[17]	XIAO Y, HE X, ZHANG H, et al. Washed microbiota transplantation effectively improves nutritional status in gastrointestinal disease-related malnourished children[J]. Nutrition, 2025, 132:112679. doi:10.1016/j.nut.2024.112679.
[18]	LIU X J, WU L H, XIE W R, et al. Faecal microbiota transplantation simultaneously ameliorated patient's essential tremor and irritable bowel syndrome[J]. Psychogeriatrics, 2020, 20(5):796-798. doi:10.1111/psyg.12583.
[19]	林国潭, 张洵. 一种基于肠型基础的肠菌移植精准配型算法模型:CN118072816A[P]. 2024-05-24.
	LIN G T, ZHANG X. A precise matching algorithm model for intestinal microbiota transplantation based on intestinal type foundation:CN118072816A[P]. 2024-05-24.
[20]	VENDRIK K, OOIJEVAAR R E, DE JONG P, et al. Fecal microbiota transplantation in neurological disorders[J]. Front Cell Infect Microbiol, 2020, 10:98. doi:10.3389/fcimb.2020.00098.
[21]	HE H, LI M, QIU Y, et al. Washed microbiota transplantation improves sleep quality in patients with sleep disorder by the gut-brain axis[J]. Front Neurosci, 2024, 18:1415167. doi:10.3389/fnins.2024.1415167.
[22]	GREEN J E, BERK M, MOHEBBI M, et al. Feasibility,acceptability,and safety of faecal microbiota transplantation in the treatment of major depressive disorder:A pilot randomized controlled trial[J]. Can J Psychiatry, 2023, 68(5):315-326. doi:10.1177/07067437221150508.
[23]	ZHANG Z, MOCANU V, DEEHAN E C, et al. Recipient microbiome-related features predicting metabolic improvement following fecal microbiota transplantation in adults with severe obesity and metabolic syndrome: a secondary analysis of a phase 2 clinical trial[J]. Gut Microbes, 2024, 16(1):2345134. doi:10.1080/19490976.2024.2345134.
[24]	LI Y, LIU Q, ZHANG L, et al. Washed microbiota transplantation reduces glycemic variability in unstable diabetes[J]. J Diabetes, 2024, 16(2):e13485. doi:10.1111/1753-0407.13485.
[25]	YANG Y, AN Y, DONG Y, et al. Fecal microbiota transplantation:no longer cinderella in tumour immunotherapy[J]. EBioMedicine, 2024, 100:104967. doi:10.1016/j.ebiom.2024.104967.
[26]	LI L, LI X, ZHONG W, et al. Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apc(min/+)mice[J]. EBioMedicine, 2019, 48:301-315. doi:10.1016/j.ebiom.2019.09.021.
[27]	WU Y, CHEN X, WU Q, et al. Research progress on fecal microbiota transplantation in tumor prevention and treatment[J]. Open Life Sci, 2025, 20(1):20220954. doi:10.1515/biol-2022-0954.
[28]	BELVONCIKOVA P, MARONEK M, GARDLIK R. Gut dysbiosis and fecal microbiota transplantation in autoimmune diseases[J]. Int J Mol Sci, 2022, 23(18):10729. doi:10.3390/ijms231810729.
[29]	HUANG C, YI P, ZHU M, et al. Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus:An EXPLORER trial[J]. J Autoimmun, 2022, 130:102844. doi:10.1016/j.jaut.2022.102844.
[30]	GRAY A N, DEFILIPP Z. Fecal microbiota transplantation for acute graft-versus-host disease after allogeneic hematopoietic cell transplantation:Expanding the horizon into pediatrics[J]. Transplant Cell Ther, 2023, 29(8):484-491. doi:10.1016/j.jtct.2023.05.007.
[31]	ZHONG H J, XIE X, CHEN W J, et al. Washed microbiota transplantation improves renal function in patients with renal dysfunction:a retrospective cohort study[J]. J Transl Med, 2023, 21(1):740. doi:10.1186/s12967-023-04570-0.
[32]	袁硕, 张一凡, 高鹏, 等. 粪菌移植技术及其应用进展[J]. 药学学报, 2025, 60(1):82-95.
	YUAN S, ZHANG Y F, GAO P, et al. The technology of fecal microbiota transplantation and its application progress[J]. Acta Pharmaceutica Sinica, 2025, 60(1):82-95. doi:10.16438/j.0513-4870.2024-0819.
[33]	BAUNWALL S, LEE M M, ERIKSEN M K, et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection:An updated systematic review and meta-analysis[J]. EClinicalMedicine, 2020,29-30:100642. doi:10.1016/j.eclinm.2020.100642.
[34]	陈启仪, 杨波, 田宏亮, 等. 菌群移植受体临床疗效与供体选择的关系[J]. 中华胃肠外科杂志, 2020, 23(Z1):69-76.
	CHEN Q Y, YANG B, TIAN H L, et al. Association between the clinical efficacy of fecal microbiota transplantation in recipients and the choice of donor[J]. Chin J Gastrointest Surg, 2020, 23(Z1):69-76. doi:10.3760/cma.j.cn.441530-20200417-00222.
[35]	HE R, LI P, WANG J, et al. The interplay of gut microbiota between donors and recipients determines the efficacy of fecal microbiota transplantation[J]. Gut Microbes, 2022, 14(1):2100197. doi:10.1080/19490976.2022.2100197.
[36]	TANG Q, JIN G, WANG G, et al. Current sampling methods for gut microbiota:A call for more precise devices[J]. Front Cell Infect Microbiol, 2020, 10:151. doi:10.3389/fcimb.2020.00151.
[37]	WANG X, ZHAO D, BI D, et al. Fecal microbiota transplantation: transitioning from chaos and controversial realm to scientific precision era[J]. Sci Bull(Beijing), 2025, 70(6):970-985. doi:10.1016/j.scib.2025.01.029.
[38]	GWEON T G, NA S Y. Next generation fecal microbiota transplantation[J]. Clin Endosc, 2021, 54(2):152-156. doi:10.5946/ce.2021.053.
[39]	MERRICK B, ALLEN L, MASIRAH M ZAIN N, et al. Regulation,risk and safety of faecal microbiota transplant[J]. Infect Prev Pract, 2020, 2(3):100069. doi:10.1016/j.infpip.2020.100069.
[40]	SINGH P, ALM E J, KELLEY J M, et al. Effect of antibiotic pretreatment on bacterial engraftment after fecal microbiota transplant(FMT)in IBS-D[J]. Gut Microbes, 2022, 14(1):2020067. doi:10.1080/19490976.2021.2020067.
[41]	中华医学会肠外肠内营养学分会, 中国国际医疗保健促进交流会加速康复外科分会, 中国微生态治疗创新联盟, 等. 菌群移植途径的选择与建立临床应用中国专家共识[J]. 中华胃肠外科杂志, 2020, 23(Z1):14-20.
	Parenteral and Enteral Nutrition Branch of Chinese Medical Association, Enhanced Recovery After Surgery Branch of China International Health Care Promotion and Exchange Association, China Microecological Treatment Innovation Alliance, et al. Chinese experts consensus on clinical practice of the selection and establishment of fecal microbiota transplantation delivery routes[J]. Chin J Gastrointest Surg, 2020, 23(Z1):14-20. doi:10.3760/cma.j.cn.441530-20200420-00228.
[42]	MARCELLA C, CUI B, KELLY C R, et al. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020[J]. Aliment Pharmacol Ther, 2021, 53(1):33-42. doi:10.1111/apt.16148.
[43]	中国菌群移植平台不良事件及其相关度动态报告[EB/OL]. (2024-11-01) [2025-07-28]. http://fmtbank.org/.
	Dynamic report on adverse events and their correlation on the Chinese FMT Bank platform[EB/OL]. (2024-11-01) [2025-07-28]. http://fmtbank.org/.
[44]	LITTLE R D, JAYAWARDANA T, KOENTGEN S, et al. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease:advances and future directions[J]. eGastroenterology, 2024, 2(1):e100006. doi:10.1136/egastro-2023-100006.
[45]	SCHMIDT T, LI S S, MAISTRENKO O M, et al. Drivers and determinants of strain dynamics following fecal microbiota transplantation[J]. Nat Med, 2022, 28(9):1902-1912. doi:10.1038/s41591-022-01913-0.
[46]	SMILLIE C S, SAUK J, GEVERS D, et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation[J]. Cell Host Microbe, 2018, 23(2):229-240.e5. doi:10.1016/j.chom.2018.01.003.
[47]	KULLAR R, GOLDSTEIN E, JOHNSON S, et al. Lactobacillus bacteremia and probiotic:A review[J]. Microorganisms, 2023, 11(4):896. doi:10.3390/microorganisms11040896.
[48]	SADA R M, MATSUO H, MOTOOKA D, et al. Clostridium butyricum bacteremia associated with probiotic use,Japan[J]. Emerg Infect Dis, 2024, 30(4):665-671. doi:10.3201/eid3004.231633.
[49]	TEIGEN L M, HOEG A, ZEHRA H, et al. Nutritional optimization of fecal microbiota transplantation in humans:a scoping review[J]. Gut Microbes, 2025, 17(1): 2446378. doi:10.1080/19490976.2024.2446378.